生物科技领域近日迎来了一次重要的突破，基因编辑技术CRISPR 3.0的临床数据正式公布，引发了市场的广泛关注。这一技术的进展不仅标志着医学研究进入了一个全新的阶段，同时也为相关股票带来了显著的上涨趋势，生物科技股集体爆发成为市场热议的话题。

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing ...

today announced a licensing agreement to integrate Synthego's high-fidelity hfCas12Max CRISPR system into Vita's cell therapeutic programs. This nonexclusive sublicense grants Vita Therapeutics ...

REDWOOD CITY, Calif., April 8, 2025 /PRNewswire/ -- Synthego and Vita Therapeutics, Inc. today announced a licensing agreement to integrate Synthego's high-fidelity hfCas12Max CRISPR system into ...

In a secret location in the United States, two white wolves are lounging in the grass in a sunny, roughly one-acre enclosure. It’s early spring and a chill wind blows through bare trees nearby.

CRISPR Therapeutics has a 12-month low of $30.96 and a 12-month high of $67.88. CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

The field of genetic engineering has been fundamentally altered by the advent of Clustered Regularly Interspaced Short Palindromic Repeats, more commonly known as CRISPR. Originally discovered as a ...